Abstract
Mucosal healing (MH) has emerged as an important treatment goal for patients with IBD. Historically, the therapeutic goals of induction and maintenance of clinical remission seemed insufficient to change the natural history of IBD. Evidence has now accumulated to show that MH can alter the course of IBD, as it is associated with sustained clinical remission, and reduced rates of hospitalization and surgical resection. In patients with ulcerative colitis, MH may represent the ultimate therapeutic goal because inflammation is limited to the mucosa. In patients with Crohn's disease, which is a transmural disease, MH could be considered as a minimum therapeutic goal. This Review focuses on the definition of MH and discusses the ability of each available IBD medication to induce and maintain MH. The importance of achieving MH is also discussed and literature that demonstrates improvement of disease course with MH is reviewed. Finally, we discuss how best to integrate the treatment end point of MH into clinical practice for the management of patients with IBD.
Key Points
-
The ideal definition of mucosal healing (MH) could be complete endoscopic healing of all inflammatory and ulcerative lesions of the gut mucosa in Crohn's disease (CD) and ulcerative colitis (UC)
-
In CD, an endoscopic response to treatment can be defined as a significant change of endoscopic disease activity score, such as the CDEIS or the SES-CD
-
In UC, MH can be achieved with corticosteroids, 5-aminosalicylates, immunosuppressive drugs and biological agents, and can be maintained with 5-aminosalicylates, immunosuppressive drugs and biological agents
-
In CD, MH can be achieved with corticosteroids, enteral nutrition (in pediatric patients), immunosuppressive drugs and biological agents, and can be maintained with immunosuppressive drugs and biological agents
-
MH is a more objective end point than clinical remission for evaluating inflammatory disease activity and should be used in both therapeutic trials and clinical practice for the management of IBD
-
MH can alter the natural history of IBD by reducing hospitalization rate and the lifetime risk for surgery
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Podolsky, D. K. Inflammatory bowel disease. N. Engl. J. Med. 347, 417–429 (2002).
Sandborn, W. J. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135, 1442–1447 (2008).
Greenberg, G. R. et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110, 45–51 (1996).
Munkholm, P., Langholz, E., Davidsen, M. & Binder, V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand. J. Gastroenterol. 30, 699–706 (1995).
van Dullemen, H. M. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129–135 (1995).
Arnott, I. D., Watts, D. & Ghosh, S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment. Pharmacol. Ther. 16, 857–867 (2002).
Kane, S. Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflamm. Bowel Dis. doi:10.1002/ibd.20779
Lichtenstein, G. R. & Rutgeerts, P. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. doi:10.1002/ibd.20997
Rutgeerts, P., Vermeire, S. & Van Assche, G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 56, 453–455 (2007).
Sandborn, W. J. et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122, 512–530 (2002).
Sostegni, R. et al. Review article: Crohn's disease: monitoring disease activity. Aliment. Pharmacol. Ther. 17 (Suppl. 2), 11–17 (2003).
Fefferman, D. S. & Farrell, R. J. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin. Gastroenterol. Hepatol. 3, 11–24 (2005).
D'Haens, G. et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132, 763–786 (2007).
Mary, J. Y. & Modigliani, R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30, 983–989 (1989).
Rutgeerts, P. et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63, 433–442 (2006).
Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 60, 505–512 (2004).
Rutgeerts, P. et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99, 956–963 (1990).
Rutgeerts, P. et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 25, 665–672 (1984).
Efthymiou, A. et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm. Bowel Dis. 14, 1542–1547 (2008).
Gal, E., Geller, A., Fraser, G., Levi, Z. & Niv, Y. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig. Dis. Sci. 53, 1933–1937 (2008).
Truelove, S. C. & Witts, L. J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 2, 1041–1048 (1955).
Baron, J. H., Connell, A. M. & Lennard-Jones, J. E. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J. 1, 89–92 (1964).
Powell-Tuck, J., Bown, R. L. & Lennard-Jones, J. E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand. J. Gastroenterol. 13, 833–837 (1978).
Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625–1629 (1987).
Sutherland, L. R. et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92, 1894–1898 (1987).
Feagan, B. G. et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352, 2499–2507 (2005).
Hanauer, S. et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol. 88, 1188–1197 (1993).
Hanauer, S. B. et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. US Budesonide enema study group. Gastroenterology 115, 525–532 (1998).
Lemann, M. et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment. Pharmacol. Ther. 9, 557–562 (1995).
Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298, 82–86 (1989).
de Lange, T., Larsen, S. & Aabakken, L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 4, 9 (2004).
Travis, S. P. et al. Developing an ulcerative colitis endocscopic index of severity (UCEIS): results of pilot phase. Gut 40 (Suppl. 1), A-201 (2008).
Green, J. R., Mansfield, J. C., Gibson, J. A., Kerr, G. D. & Thornton, P. C. A double-blind comparison of balsalazide, 6. 75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment. Pharmacol. Ther. 16, 61–68 (2002).
Hanauer, S. B. et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can. J. Gastroenterol. 21, 827–834 (2007).
Hanauer, S. B. et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. 100, 2478–2485 (2005).
Kamm, M. A. et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132, 66–75 (2007).
Kruis, W. et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58, 233–240 (2009).
Malchow, H. & Gertz, B. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment. Pharmacol. Ther. 16, 415–423 (2002).
Mansfield, J. C. et al. A double-blind comparison of balsalazide, 6. 75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 16, 69–77 (2002).
Vecchi, M. et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment. Pharmacol. Ther. 15, 251–256 (2001).
Marshall, J. K. & Irvine, E. J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40, 775–781 (1997).
Lichtenstein, G. R. et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 5, 95–102 (2007).
Sandborn, W. J. et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther. 26, 205–215 (2007).
Modigliani, R. et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98, 811–818 (1990).
Olaison, G., Sjodahl, R. & Tagesson, C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31, 325–328 (1990).
Gross, V. et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment. Pharmacol. Ther. 23, 303–312 (2006).
Regueiro, M., Loftus, E. V. Jr, Steinhart, A. H. & Cohen, R. D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm. Bowel Dis. 12, 979–994 (2006).
Truelove, S. C. & Witts, L. J. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br. Med. J. 2, 375–378 (1954).
Truelove, S. C. & Jewell, D. P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1, 1067–1070 (1974).
Lofberg, R. et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110, 1713–1718 (1996).
Lee, F. I. et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 38, 229–233 (1996).
Manguso, F. & Balzano, A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment. Pharmacol. Ther. 26, 21–29 (2007).
Campieri, M. et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther. 17, 1471–1480 (2003).
Rizzello, F. et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 16, 1109–1116 (2002).
Sandborn, W. J. et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 109, 1808–1817 (1995).
D'Haens, G., Geboes, K., Ponette, E., Penninckx, F. & Rutgeerts, P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112, 1475–1481 (1997).
D'Haens, G., Geboes, K. & Rutgeerts, P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest. Endosc. 50, 667–671 (1999).
Mantzaris, G. J. et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm. Bowel Dis. 15, 375–382 (2009).
Colombel, J. et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biological therapy. Gut 57 (Suppl. 2), A-1 (2008).
Paoluzi, O. A. et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. 16, 1751–1759 (2002).
Ardizzone, S. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55, 47–53 (2006).
Feagan, B. G. et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332, 292–297 (1995).
Kozarek, R. A. et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann. Intern. Med. 110, 353–356 (1989).
Manosa, M. et al. Does methotrexate induce mucosal healing in Crohn's disease? Inflamm. Bowel Dis. doi:10.1002/ibd.21015
Baldassano, R. et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 98, 833–838 (2003).
Borrelli, O. et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36, 342–347 (2004).
D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).
D'Haens, G. et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116, 1029–1034 (1999).
Geboes, K. et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr. Med. Res. Opin. 21, 1741–1754 (2005).
Gheorghe, L. et al. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Rom. J. Gastroenterol. 12, 7–13 (2003).
Rutgeerts, P. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126, 402–413 (2004).
Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).
Rutgeerts, P. et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease—first results of the EXTEND Trial. Gastroenterology 136 (Suppl. 1), A-116 (2009).
Hébuterne, X. et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the music clinical trials. Gut 57 (Suppl. 2), A-15 (2008).
Barreiro, M., Lorenzo, A., Mera, J. & Dominguez-Munoz, E. Prospective, open pilot study for evaluating the clinical efficacy and mucosal healing rate of infliximab in steroid-dependent ulcerative colitis. Gastroenterology 134 (Suppl. 1), A-667 (2008).
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).
Afif, W. et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm. Bowel Dis. 15, 1302–1307 (2009).
Targan, S. R. et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132, 1672–1683 (2007).
Rutgeerts, P. et al. Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1). Gastroenterology 126 (Suppl. 2), A-208 (2004).
Sandborn, W. J. et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912–1925 (2005).
Afzal, N. A. et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment. Pharmacol. Ther. 20, 167–172 (2004).
Akobeng, A. K. & Thomas, A. G. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. CD005984 (2007).
Borrelli, O. et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4, 744–753 (2006).
Fell, J. M. et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment. Pharmacol. Ther. 14, 281–289 (2000).
Zachos, M., Tondeur, M. & Griffiths, A. M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. CD000542 (2007).
Prantera, C., Kohn, A., Mangiarotti, R., Andreoli, A. & Luzi, C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am. J. Gastroenterol. 89, 513–518 (1994).
Borody, T. J. et al. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig. Liver Dis. 39, 438–444 (2007).
D'Haens, G. et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120, 1323–1329 (2001).
Van Assche, G. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125, 1025–1031 (2003).
Ewe, K., Bottger, T., Buhr, H. J., Ecker, K. W. & Otto, H. F. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur. J. Gastroenterol. Hepatol. 11, 277–282 (1999).
Hellers, G. et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 116, 294–300 (1999).
Travis, S. P. et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 (Suppl. 1), i16–35 (2006).
Lemann, M. et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128, 1812–1818 (2005).
Kamm, M. A. et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm. Bowel Dis. 15, 1–8 (2009).
Kamm, M. A. et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57, 893–902 (2008).
D'Haens, G. et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 122, A-618 (2002).
Baert, F. J. et al. Mucosal healing predicts sustained clinical remission in early Crohn's disease. Gastroenterology 134 (Suppl. 1), A-640 (2008).
Wright, R. & Truelove, S. R. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am. J. Dig. Dis. 11, 847–857 (1966).
Riley, S. A., Mani, V., Goodman, M. J., Dutt, S. & Herd, M. E. Microscopic activity in ulcerative colitis: what does it mean? Gut 32, 174–178 (1991).
Bitton, A. et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120, 13–20 (2001).
Sandborn, W. J. et al. Infliximab induces and maintains mucosal healing in ulcerative colitis patients: the ACT trials. Am. J. Gastroenterol. 100 (Suppl.), S310 (2005).
Meucci, G. et al. Prognostic significance of endoscopic remission in patients with active ulceratice colitis treated with oral and topical mesalazine: preliminary results from a prospective multicenter study. Gastroenterology 130 (Suppl. 2), A-197 (2006).
Allez, M. et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am. J. Gastroenterol. 97, 947–953 (2002).
Carbonnel, F. et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment. Pharmacol. Ther. 14, 273–279 (2000).
Schnitzler, F. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. 15, 1295–1301 (2009).
Ferrante, M. et al. Long-term outcome after infliximab for refractory ulcerative colitis. Journal of Crohn's and Colitis 2, 219–225 (2008).
Froslie, K. F., Jahnsen, J., Moum, B. A. & Vatn, M. H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412–422 (2007).
Solberg, I. C., Lygren, I., Jahnsen, J., Vatn, M. & Moum, B. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease Gut 57 (Suppl. 2), A-15 (2008).
Gupta, R. B. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133, 1099–1105 (2007).
Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 441, 431–436 (2006).
Rutter, M. D. et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53, 1813–1816 (2004).
Rutter, M. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126, 451–459 (2004).
Lemann, M. Review article: can post-operative recurrence in Crohn's disease be prevented? Aliment. Pharmacol. Ther. 24 (Suppl. 3), 22–28 (2006).
Rutgeerts, P. Review article: recurrence of Crohn's disease after surgery—the need for treatment of new lesions. Aliment. Pharmacol. Ther. 24 (Suppl. 3), 29–32 (2006).
Louis, E. et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with imunnosuppressors: interim analysis of a prospective cohort study. Gut 57 (Suppl. 2), A-66 (2008).
Rimola, J. et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 58, 1113–1120 (2009).
Hanai, H. et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 49, 1438–1443 (2004).
Sipponen, T. et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm. Bowel Dis. 14, 40–46 (2008).
Schoepfer, A. M. et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm. Bowel Dis. 15, 1851–1858 (2009).
Geboes, K. & Dalle, I. Influence of treatment on morphological features of mucosal inflammation. Gut 50 (Suppl. 3), III37–42 (2002).
Acknowledgements
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. Pineton de Chambrun declares no competing interests. L. Peyrin-Biroulet is a Consultant for Abbott and UCB, receives research support from UCB and is on the Speaker's bureau for Centocor. J.F. Colombel is a Consultant and is on the Speaker's bureau for Abbott, Centocor JCB, Schering Plough and UCB. M. Lémann is on the Speaker's bureau for Abbott, Astra, Ferring, Schering Plough, Shire, PDL and UCB. He has received study grants or educational grants from Abbott, Astra, BMS, Ferring, Sanofi-Aventis, Schering Plough, Shire, Novartis, PDL, Novartis and UCB. He is a Consultant for Abbott, Centocor, Elan, Ferring, Millenium, Schering Plough, Shire, Novartis, Pfizer, PDL and UCB.
Rights and permissions
About this article
Cite this article
Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M. et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 7, 15–29 (2010). https://doi.org/10.1038/nrgastro.2009.203
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.203